---
title: "Regulatory roadmap: Medicinal product, European Union and Switzerland"
url: https://normiq.app/en/roadmap/eu-switzerland/medicinal-product
language: en
updated: 2026-11-17
---

# Regulatory roadmap: Medicinal product, European Union and Switzerland

11 phases · 44 steps

This is the order in which Normiq organises market access for the market "European Union and Switzerland" and the category "Medicinal product". Each step has a detailed guide — how to proceed, best practices, common mistakes, reference articles — reserved for Normiq accounts.

1. Phase 1

   ## Integrity and transparency (Switzerland)

   Swiss obligations governing advantages granted to healthcare professionals and the transparency of discounts. Concerns sales and marketing as much as regulatory affairs.

   1. ### Switzerland — determine whether transparency applies to you

      required · 10 d

      Establish whether your products and commercial practices fall within Art. 55 and 56 of the Therapeutic Products Act.

   2. ### Switzerland — account for discounts and rebates

      required · 20 d

      Discounts and rebates must appear in supporting documents, accounts and books, and be disclosed to the Federal Office of Public Health on request.

   3. ### Switzerland — set up internal control arrangements

      required · 30 d

      A designated person, ten years of retention for agreements, and a list of those who received lawful advantages.

   4. ### Switzerland — congresses, training and paid services

      required · 20 d

      Hard thresholds: an own contribution of one third or one fifth, meals capped at CHF 100, advantages of modest value capped at CHF 300 a year.

2. Phase 2

   ## Molecule Discovery

   Therapeutic target identification and drug candidate development

   1. ### Therapeutic Target Identification

      required · 270 d

      Identification of a molecular target (protein, receptor, enzyme) involved in a pathology

   2. ### Screening and Hit Identification

      required · 225 d

      High-throughput screening (HTS) of compound libraries to identify active molecules

   3. ### Lead Optimization

      required · 635 d

      Chemical modification of hits to improve potency, selectivity and pharmacokinetic properties

3. Phase 3

   ## Preclinical Development

   Toxicology, pharmacology, and pharmacokinetic studies

   1. ### Studies de pharmacologie in vitro

      required · 225 d

      Characterization of the pharmacological activity of the drug candidate in cellular models

   2. ### Studies de pharmacologie in vivo

      required · 270 d

      Efficacy studies on animal models of the disease

   3. ### GLP genotoxicity (in vitro and in vivo)

      required · 105 d

      Ames test, chromosomal aberrations, micronucleus test

   4. ### GLP 28-day repeated-dose toxicity

      required · 126 d

      GLP 28-day toxicity study (rodents and non-rodents)

   5. ### Safety pharmacology (hERG, QTc)

      required · 135 d

      Studies cardio-vasculaires, respiratoires, SNC

   6. ### Pharmacokinetic (PK) and ADME Studies

      required · 225 d

      Absorption, distribution, metabolism, excretion in animals

   7. ### CMC/Quality Development (Module 3)

      required · 450 d

      Manufacturing process development, quality controls, stability

4. Phase 4

   ## Application d'clinical trial (CTA CH + EU)

   Parallel submission: CTIS (EU) and Swissmedic (CH)

   1. ### Preparation dossier IND/CTA (Modules 2-5)

      required · 105 d

      Dossier CTD Modules 2, 3, 4 + protocol clinique + brochure investigateur

   2. ### CTIS Submission (European Union)

      required · 90 d

      Submission via Clinical Trial Intraining System (CTIS) pour sites EU

   3. ### Submission Swissmedic (Switzerland)

      required · 75 d

      Submission CTA via portail eSubmission Swissmedic pour sites CH

   4. ### CTA evaluation and approval (CH + EU)

      required · 90 d

      Obtain approvals from Swissmedic and EU authorities (MSC)

5. Phase 5

   ## Clinical Trial Phase I (CH + EU)

   First-in-Human - Safety and tolerability (CH and/or EU sites)

   1. ### First-in-Human (FIH) - Dose escalation

      required · 270 d

      First human administration, cautious dose escalation

   2. ### Studies PK/PD Phase I

      required · 135 d

      Pharmacokinetics, pharmacodynamics, drug-drug interaction, food effect

6. Phase 6

   ## Clinical Trial Phase II (CH + EU)

   Proof of concept and dose determination (multinational trials)

   1. ### Phase IIa - Proof of Concept (PoC)

      required · 545 d

      First efficacy evaluation on a small patient cohort (100-200)

   2. ### Phase IIb - Dose-finding

      required · 550 d

      Determination of the optimal dose for Phase III (200-300 patients)

7. Phase 7

   ## Clinical Trial Phase III (CH + EU)

   Studies pivotales multicentriques - Base de l'AMM

   1. ### Studies pivotales Phase III (2 essais minimum)

      required · 1095 d

      Multicenter randomized controlled trials (300-3000+ patients)

   2. ### Long-Term Safety Studies

      required · 365 d

      Collection of safety data under prolonged exposure

   3. ### Studies de toxicologie chronique (si indication chronique)

      recommended · 910 d

      6-12 month toxicity, carcinogenicity based on intended treatment duration

8. Phase 8

   ## GMP Certification (CH + EU)

   GMP Certification avec reconnaissance mutuelle Switzerland-EU (MRA)

   1. ### GMP Compliance (EU GMP / PIC/S)

      required · 455 d

      Site compliance with EU GMP standards (EudraLex Vol 4) and PIC/S GMP

   2. ### GMP Inspection et certification

      required · 150 d

      Inspection by the competent authority (Swissmedic OR an EU authority)

   3. ### Registration EudraGMDP (pour dossier EU)

      required · 35 d

      Swissmedic enters GMP data into the EudraGMDP database

9. Phase 9

   ## Preparation dossiers CTD/eCTD (CH + EU)

   MA dossier compilation - Modules 2-5 identical, Module 1 different

   1. ### Compilation of CTD Modules 2-5 (common CH + EU)

      required · 635 d

      Module 2: Summaries / Module 3: Quality CMC / Module 4: Non-Clinical / Module 5: Clinical

   2. ### Preparation Module 1 - EU (SmPC, PIL)

      required · 105 d

      EU-specific Module 1: EMA forms, SmPC, Patient Information Leaflet

   3. ### Preparation Module 1 - CH (Fachintraining)

      required · 105 d

      Switzerland-specific Module 1: Swissmedic forms, Fachinformation, patient information

   4. ### eCTD conversion (CH + EU)

      required · 75 d

      Conversion of both dossiers (CH and EU) into electronic eCTD format

   5. ### Pre-submission meetings (EMA + Swissmedic)

      recommended · 75 d

      Pre-submission meetings with EMA (7 months in advance) and Swissmedic

10. Phase 10

    ## MA Submission and Evaluation (CH + EU)

    PARALLEL submission to EMA and Swissmedic — Major time savings

    1. ### MAA Submission to EMA (Centralised Procedure)

       required · 30 d

       Submission of complete eCTD dossier via EMA centralized procedure

    2. ### MA Submission to Swissmedic (Standard Procedure)

       required · 30 d

       Submission of eCTD dossier via the Swissmedic portal

    3. ### EMA evaluation by CHMP

       required · 375 d

       CHMP assessment: 210 active days + response time (LoQ)

    4. ### European Commission approval

       required · 67 d

       Final European Commission decision following CHMP opinion

    5. ### Swissmedic evaluation (standard procedure)

       required · 330 d

       Quality, safety and efficacy assessment by Swissmedic

    6. ### Obtention AMM Switzerland

       required · 15 d

       Marketing authorisation issued by Swissmedic

11. Phase 11

    ## Post-authorisation et pharmacovigilance (CH + EU)

    Harmonized CH + EU pharmacovigilance system

    1. ### EU pharmacovigilance system (PSMF)

       required · 75 d

       PSMF (Pharmacovigilance System Master File) + EU/EEA-based QPPV

    2. ### CH pharmacovigilance system (Swissmedic)

       required · 75 d

       Qualified person responsible for adverse reaction reporting (Art. 59 TPA)

    3. ### Risk Management Plan (RMP) - ICH E2E

       required · 30 d

       Harmonized CH + EU risk management plan

    4. ### Periodic Safety Update Reports (PSURs)

       required · 30 d

       Periodic safety reports (6 months initially, then annually, then every three years)

    5. ### MA renewal (CH + EU)

       required · 135 d

       Renewal after 5 years (EU) or per MA terms (CH)

The detailed guide for each step — how to proceed, best practices, common mistakes — is reserved for Normiq accounts.

## Track these deadlines device by device

Normiq places every deadline in your device's roadmap, with the steps that lead to it. Free 7-day trial.

[Open this roadmap in Normiq](https://normiq.app/signup)

## Other pathways on this market

- [Class A IVD](https://normiq.app/en/roadmap/eu-switzerland/ivd-class-a)
- [Class B IVD](https://normiq.app/en/roadmap/eu-switzerland/ivd-class-b)
- [Class C IVD](https://normiq.app/en/roadmap/eu-switzerland/ivd-class-c)
- [Class D IVD](https://normiq.app/en/roadmap/eu-switzerland/ivd-class-d)
- [Class I medical device](https://normiq.app/en/roadmap/eu-switzerland/class-i)
- [Class IIa medical device](https://normiq.app/en/roadmap/eu-switzerland/class-iia)
- [Class IIb medical device](https://normiq.app/en/roadmap/eu-switzerland/class-iib)
- [Class III medical device](https://normiq.app/en/roadmap/eu-switzerland/class-iii)
